Medincell: Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2025
0mins
Source: Yahoo Finance
Medincell and Teva Partnership: Medincell will receive a $5 million milestone payment from Teva following the completion of the SOLARIS study for olanzapine Long-Acting Injectable (LAI) aimed at treating schizophrenia, with plans for regulatory submission in the US.
Clinical Trial Results: The SOLARIS trial demonstrated that TEV-'749 met its primary efficacy endpoint, showing significant improvements in symptoms and quality of life for patients, while also eliminating the risk of Post-Injection Delirium/Sedation Syndrome (PDSS).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
